Quick Answer
CHINA PHARMA HOLDINGS, INC. reported Research And Development Expense of $283.9 thousand for the year ending 2024.
- CHINA PHARMA HOLDINGS, INC. showed an increase of +18.3% in Research And Development Expense from 2023 to 2024.
- This data is from CHINA PHARMA HOLDINGS, INC.'s annual report (Form 10-K), filed with the SEC on March 31, 2025.
- XBRL data for this metric is available from 2012 to 2024 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: $444.4 thousand | Q2 2014: $1.90 million | Q3 2014: $181.8 thousand | Q1 2015: $160.8 thousand | Q2 2015: $174.9 thousand | Q3 2015: $405.4 thousand | Q1 2016: $93.4 thousand | Q2 2016: $96.7 thousand | Q3 2016: $99.1 thousand | Q1 2017: $26.1 thousand | Q2 2017: $21.5 thousand | Q3 2017: $27.5 thousand | Q1 2018: $22.2 thousand | Q2 2018: $23.7 thousand | Q3 2018: $62.1 thousand | Q1 2019: $69.9 thousand | Q2 2019: $66.0 thousand | Q3 2019: $39.7 thousand | Q1 2020: $48.8 thousand | Q2 2020: $30.0 thousand | Q3 2020: $37.6 thousand | Q1 2021: $190.1 thousand | Q2 2021: $53.5 thousand | Q3 2021: $21.4 thousand | Q1 2022: $54.0 thousand | Q2 2022: $15.1 thousand | Q3 2022: $88.7 thousand | Q1 2023: $23.0 thousand | Q2 2023: $23.7 thousand | Q3 2023: $45.8 thousand | Q1 2024: $31.5 thousand | Q2 2024: $164.3 thousand | Q3 2024: $87.6 thousand | Q1 2025: $29.6 thousand | Q2 2025: $21.0 thousand | Q3 2025: $40.3 thousand.
- Over the full 13 years of available data (2012 to 2024), CHINA PHARMA HOLDINGS, INC.'s Research And Development Expense has declined by 35.3%.
- Historical annual values: Fiscal year 2024: $283.9 thousand | Fiscal year 2023: $240.1 thousand | Fiscal year 2022: $185.9 thousand | Fiscal year 2021: $319.0 thousand | Fiscal year 2020: $378.0 thousand | Fiscal year 2019: $229.6 thousand | Fiscal year 2018: $172.4 thousand | Fiscal year 2017: $90.5 thousand | Fiscal year 2016: $366.0 thousand | Fiscal year 2015: $961.9 thousand | Fiscal year 2014: $2.80 million | Fiscal year 2013: $1.68 million | Fiscal year 2012: $438.7 thousand.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: